O&jeetive: To investigate the effects of grape&tit juice on the pharmacokinetics and dynamics of midaZ4BlanL Met&oh Eight healthy male subjects participated in this open crossover study. Intravenous (5 mg) or oral (15 mg) midazolam was administered after pretreatment with water or grapefruit juice.
A pharmacokinetic interaction between roxithromycin and midazolam
β Scribed by J. T. Backman; K. Aranko; J. -J. Himberg; K. T. Olkkola
- Publisher
- Springer
- Year
- 1994
- Tongue
- English
- Weight
- 506 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
β¦ Synopsis
The interaction between roxithromycin and midazolam was investigated in a double-blind, randomised crossover study of two phases. Ten healthy volunteers were given roxithromycin (300 mg) or placebo once daily for 6 days. On the sixth day they ingested 15 mg midazolam. Plasma samples were collected and psychomotor performance measured for 17 h.
Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 gg. mk ~. rain and the elimination half-lives from 1.7 to 2.2 h. In psychomotor performance only minor differences were seen between the treatments in one of the measured psychomotor parameters.
Thus, in contrast to the strong interaction between erythromycin and midazolam, the interaction between roxithromycin and midazolam appears less likely to be clinically significant.
π SIMILAR VOLUMES
Previous reports have indicated that administration of the calcium antagonist diltiazem results in major changes in the pharmacokinetics of cyclosporin A (CyA). A new clinical trial was undertaken in 22 renal transplant patients receiving a constant dose of cyclosporin to further explore this intera
## Objective: Case report of a pharmacokinetic interaction between diltiazem and nortriptyline. ## Methods: Determination of plasma nortriptyline concentrations by hplc. calculation of nortriptyline clearances and half-life by formulae used routinely in therapeutic drug monitoring. ## Results:
The effects of piroxicam (40 mg) on the pharmacokinetics of ranitidine (150 mg) and of ranitidine (150 mg bid) on the pharmacokinetics of piroxicam (20 mg) were assessed in two 2-way crossover studies in two groups of 18 healthy male subjects. In the first study there were no statistically significa